Molecular pathways: A novel approach to targeting hypoxia and improving radiotherapy efficacy via reduction in oxygen demand

Clinical Cancer Research

Volumn 21, Issue 9, 2015, Pages 1995-2000

  Lin, Alexander ^a   Maity, Amit ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; CISPLATIN; DICLOFENAC; INDOMETACIN; METFORMIN; NELFINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PIROXICAM; RADIOPHARMACEUTICAL AGENT; ROSIGLITAZONE; UNCLASSIFIED DRUG; RADIOSENSITIZING AGENT;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONCENTRATION RESPONSE; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG USE; ELECTRON SPIN RESONANCE; EVIDENCE BASED MEDICINE; EXPERIMENTAL HYPOXIA; FIBROSARCOMA; HUMAN; LARYNX CANCER; LIVER CANCER; LUNG ADENOCARCINOMA; MICELLE; MITOCHONDRIAL RESPIRATION; NON SMALL CELL LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY CHAIN; RISK BENEFIT ANALYSIS; TRANSLATIONAL RESEARCH; TUMOR GROWTH; TUMOR GROWTH INHIBITION (PERCENTAGE); TUMOR XENOGRAFT; CELL HYPOXIA; DRUG EFFECTS; NEOPLASMS; PATHOPHYSIOLOGY; PHYSIOLOGY;

CELL HYPOXIA; HUMANS; NEOPLASMS; OXYGEN CONSUMPTION; RADIATION-SENSITIZING AGENTS;

EID: 84941945907     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0858     Document Type: Article

References (49)

1. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007;9:1221-35.
2. Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Collins R, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004;64:1886-92.
3. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7.
4. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393-410.
5. Hall EJ, Giaccia AJ. Oxygen effect and reoxygenation. In: radiobiology for the radiologist. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012. p. 86-103.
6. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
7. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680-7.
8. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. J Radiat Oncol Biol Phys 1997;38:285-9.
9. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24.
10. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070-5.
11. Henk JM, Kunkler PB, Smith CW. Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial. Lancet 1977;2:101-3.
12. Henk JM, Smith CW. Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial. Lancet 1977; 2:104-5.
13. Watson ER, Halnan KE, Dische S, Saunders MI, Cade IS, McEwen JB, et al. Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix. Br J Radiol 1978;51:879-87.
14. Cade IS, McEwen JB, Dische S, Saunders MI, Watson ER, Halnan KE, et al. Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the bladder. Br J Radiol 1978;51:876-8.
15. Overgaard J. Sensitization of hypoxic tumour cells-clinical experience. Int J Radiat Biol 1989;56:801-11.
16. Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jorgensen K, Sandberg E, et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989;16:1065-8.
17. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-46.
18. Lee DJ, Cosmatos D, Marcial VA, Fu KK, Rotman M, Cooper JS, et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995;32:567-76.
19. Overgaard J. Clinical evaluation of nitroimidazoles asmodifiers of hypoxia in solid tumors. Oncol Res 1994;6:509-18.
20. Medical Research Council Working Party on Advanced Carcinoma of the Cervix. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol 1993;26:93-103.
21. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 2011;100:22-32.
22. Haffty BG, Son YH, Sasaki CT, Papac R, Fischer D, Rockwell S, et al. MitomycinCas an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 1993;27:241-50.
23. Weissberg JB, Son YH, Papac RJ, Sasaki C, Fischer DB, Lawrence R, et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1989;17:3-9.
24. Dobrowsky W, Naude J, Dobrowsky E, Millesi W, Pavelka R, Grasl M, et al. Mitomycin C (MMC) and unconventional fractionation (V-CHART) in advanced head and neck cancer. Acta Oncol 1995;34:270-2.
25. Grau C, Prakash Agarwal J, Jabeen K, Rab Khan A, Abeyakoon S, Hadjieva T, et al. Radiotherapy with or withoutmitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. Radiother Oncol 2003;67:17-26.
26. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28:2989-95.
27. Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28:4142-8.
28. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomographydetected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-104.
29. Secomb TW, Hsu R, Dewhirst MW. Synergistic effects of hyperoxic gas breathing and reduced oxygen consumption on tumor oxygenation: a theoretical model. Int J Radiat Oncol Biol Phys 2004;59:572-8.
30. Durand RE, Biaglow JE. Radiosensitization of hypoxic cells of an in vitro tumor model by respiratory inhibitors. Radiat Res 1977;69:359-66.
31. Biaglow JE, Manevich Y, Leeper D, Chance B, Dewhirst MW, Jenkins WT, et al. MIBG inhibits respiration: potential for radio- and hyperthermic sensitization. Int J Radiat Oncol Biol Phys 1998;42:871-6.
32. Diepart C, Karroum O, Magat J, Feron O, Verrax J, Calderon PB, et al. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res 2012;72:482-90.
33. Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance druginduced apoptosis in human leukemia cells by a reactive oxygen speciesmediated mechanism. J Biol Chem 2003;278:37832-9.
34. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004;53:1052-9.
35. Zannella VE, Dal Pra A, Muaddi H, McKee TD, Stapleton S, Sykes J, et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res 2013;19:6741-50.
36. Storozhuk Y, Hopmans SN, Sanli T, Barron C, Tsiani E, Cutz JC, et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 2013;108: 2021-32.
37. Simone CB II, Csiki I, Heskel M, Gabriel P, Kim H, Corradetti MN, et al. Metformin as a radiosensitizer for lung cancer [abstract]. In: Proceedings of the 15th World Conference on Lung Cancer; 2013 Oct 27-31; Sydney, Australia. Vancouver (BC): IASLC; 2013. Abstract nr MO05.10.
38. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 2013;52:1002-9.
39. Skinner HD, Crane CH, Garrett CR, Eng C, Chang GJ, Skibber JM, et al. Metformin use and improved response to therapy in rectal cancer. Cancer Med 2013;2:99-107.
40. Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009;69:6347-54.
41. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 2012;72:239-48.
42. Pore N, Gupta AK, Cerniglia GJ, Jiang Z, Bernhard EJ, Evans SM, et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 2006;66:9252-9.
43. Cerniglia GJ, Pore N, Tsai JH, Schultz S, Mick R, Choe R, et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS ONE 2009;4:e6539.
44. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005;65:8256-65.
45. Kelly CJ, Hussien K, Fokas E, Kannan P, Shipley RJ, Ashton TM, et al. Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. Radiother Oncol 2014;111: 72-80.
46. Crokart N, Radermacher K, Jordan BF, Baudelet C, Cron GO, Gregoire V, et al. Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Res 2005;65: 7911-6.
47. Danhier F, Danhier P, Magotteaux N, De Preter G, Ucakar B, Karroum O, et al. Electron paramagnetic resonance highlights that the oxygen effect contributes to the radiosensitizing effect of paclitaxel. PLoS ONE 2012;7: e40772.
48. Zhang T, Zhang L, Zhang T, Fan J, Wu K, Guan Z, et al. Metformin sensitizes prostate cancer cells to radiation through EGFR/p-DNA-PKCS in vitro and in vivo. Radiat Res 2014;181:641-9.
49. Lin A, Hahn SM. Hypoxia imaging markers and applications for radiation treatment planning. Semin Nucl Med 2012;42:343-52.